顺铂化疗后程加用地塞米松对迟发性恶心呕吐的防治作用观察被引量：12

下载PDF

导出

摘要目的观察顺铂(DDP)化疗后程加用地塞米松对迟发性恶心呕吐的防治作用。方法 80例恶性肿瘤患者,采用DDP为基础的化疗方案化疗(DDP 60～80 mg/m2、d1),随机分为A(28例)、B(26例)、C(26例)组。A组给予阿扎司琼10 mg静滴、d 1～d 4,地塞米松5 mg静注、d 3～d 4;B组给予阿扎司琼10 mg静滴、d 1～d 4,地塞米松5 mg静注、d 1～d 4;C组给予阿扎司琼10 mg、静滴、d 1～d 4。观察各组化疗第2、3、4天恶心呕吐情况及不良反应。结果 A、B、C组恶心呕吐发生率分别为96.43%、96.15%、73.08%;A、B两组相比,P均>0.05;A、B组与C组相比,P均<0.05。A、B、C组出现不良反应者分别为10、29、7例;A、C组与B组相比,P均<0.05。结论 DDP化疗后程短期加用地塞米松可有效防治迟发性恶心呕吐,不良反应小。

作者张莹莹朱琼高向阳杜秀平韩正祥

机构地区徐州医学院附属医院

出处《山东医药》 CAS 2012年第42期46-47,共2页 Shandong Medical Journal

基金江苏省卫生厅医学科技发展基金资助项目(P200942) 徐州医学院课题(08KJ53)

关键词药物疗法顺铂肿瘤化疗并发症恶心呕吐地塞米松

分类号 R730 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemo- therapy-induced nausea and vomiting after modem antiemetics [ J ]. Cancer, 2004,100(10) :2261-2268.
2Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treat- ment of chemotherapy-induced nausea and vomiting : past, present, and future recommendations[ J]. Oncologist, 2007,12 ( 9 ) : 1143- 1150.
3Musso M, Scalone R, Bonanno V, et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy [ J ]. Support Care Cancer, 2009,17(2) :205-209.
4Brugnatelli S, Gattoni E, Grasso D, et al. Single-dose palonose- tron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients [ J ]. Tumori, 2011,97 ( 3 ) : 362-366.
5Liu Y, Zhang J, Teng Y, et al. Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen: results of a prospective randomized crossover study [ J ]. Tumori, 2009,95 ( 6 ) :691-696.
6Ho CL,Su WC, Hsieh RK, et al. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting[J]. Jpn J Clin Oncol, 2010,40(4) :294-301.
7Rimaitis K, Svitojute A, Macas A. The influence of dexamethasone and ketolgan on postoperative nausea and vomiting and estimation of risk factors in women undergoing gynecologic laparoscopic sur- geries[J]. Medieina (Kaunas) , 2010,46(4) :261-267.
8Kaushal J, Gupta MC, Kaushal V, et al. Clinical evaluation of two anticmetic combinations palonosctron dexamethasone versus ondan- setron dexamethasone in chemotherapy of head and neck cancer [ J]. Singapore Med J, 2010,51 ( 11 ) :871-875.
9Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement [ J. Support Care Cancer, 2005,13(2) :112-116.
10Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy[ J]. Br J Cancer, 2006,94 (7) :1011-1015.